
## Cathryn H Bock

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6557143/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Urologists' Perceptions of Active Surveillance and Their Recommendations for Low-risk Prostate Cancer Patients. Urology, 2021, 155, 83-90.	1.0	7
2	A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry. Blood Advances, 2020, 4, 181-190.	5.2	16
3	Prediagnostic circulating markers of inflammation and risk of oesophageal adenocarcinoma: a study within the National Cancer Institute Cohort Consortium. Gut, 2019, 68, 960-968.	12.1	25
4	Prostate Cancer National Summit's Call to Action. Clinical Genitourinary Cancer, 2019, 17, 161-168.	1.9	0
5	A study of circulating microRNAs identifies a new potential biomarker panel to distinguish aggressive prostate cancer. Carcinogenesis, 2018, 39, 556-561.	2.8	24
6	The effect of genetic variants on the relationship between statins and breast cancer in postmenopausal women in the Women's Health Initiative observational study. Breast Cancer Research and Treatment, 2018, 167, 741-749.	2.5	2
7	Renal cell carcinoma risk associated with lower intake of micronutrients. Cancer Medicine, 2018, 7, 4087-4097.	2.8	17
8	The extrema of circulating miR-17 are identified as biomarkers for aggressive prostate cancer. American Journal of Cancer Research, 2018, 8, 2088-2095.	1.4	7
9	A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1609-1618.	2.5	18
10	Female chromosome X mosaicism is age-related and preferentially affects the inactivated X chromosome. Nature Communications, 2016, 7, 11843.	12.8	86
11	Menopausal estrogen therapy and nonâ€ <scp>H</scp> odgkin's lymphoma: A <i>postâ€hoc</i> analysis of women's health initiative randomized clinical trial. International Journal of Cancer, 2016, 138, 604-611.	5.1	13
12	Characterization of Large Structural Genetic Mosaicism in Human Autosomes. American Journal of Human Genetics, 2015, 96, 487-497.	6.2	101
13	Familial clustering of breast and prostate cancer and risk of postmenopausal breast cancer in the <scp>W</scp> omen's <scp>H</scp> ealth <scp>I</scp> nitiative <scp>S</scp> tudy. Cancer, 2015, 121, 1265-1272.	4.1	33
14	Antioxidant micronutrients and the risk of renal cell carcinoma in the Women's Health Initiative cohort. Cancer, 2015, 121, 580-588.	4.1	25
15	Electric Blanket Use and Risk of Thyroid Cancer in the Women's Health Initiative Observational Cohort. Women and Health, 2015, 55, 829-841.	1.0	4
16	Reducing Prostate Cancer Racial Disparity: Evidence for Aggressive Early Prostate Cancer PSA Testing of African American Men. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1505-1511.	2.5	54
17	Genetic Susceptibility Markers of Multiple Myeloma in African-Americans. Blood, 2014, 124, 2030-2030.	1.4	0
18	Prospective Analysis of Association between Statin Use and Breast Cancer Risk in the Women's Health Initiative. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 1868-1876.	2.5	41

CATHRYN H BOCK

#	Article	IF	CITATIONS
19	Genes Associated with Prostate Cancer Are Differentially Expressed in African American and European American Men. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 891-897.	2.5	142
20	1635 AN UPDATE OF PROGRESSION FREE SURVIVAL (PFS) OF LOCALLY ADVANCED PROSTATE CANCER AMONG AFRICAN AMERICAN AND EUROPEAN AMERICAN MEN WHO HAVE UNDERGONE RADICAL PROSTATECTOMY (RP). Journal of Urology, 2012, 187, .	0.4	0
21	1201 EARLIER AGE FOR PROSTATE CANCER SCREENING OF AFRICAN AMERICAN MEN IS NEEDED TO ELIMINATE RACIAL MORTALITY DISPARITY. Journal of Urology, 2011, 185, .	0.4	2
22	Prostate Cancer Susceptibility Loci Identified on Chromosome 12 in African Americans. PLoS ONE, 2011, 6, e16044.	2.5	31
23	Racial Disparities in Prostate Cancer Incidence, Biochemical Recurrence, and Mortality. Prostate Cancer, 2011, 2011, 1-2.	0.6	15
24	Red Wine Consumption is Inversely Associated with 2-Amino-1-Methyl-6-Phenylimidazo[4,5- <i>b</i> ]Pyridine–DNA Adduct Levels in Prostate. Cancer Prevention Research, 2011, 4, 1636-1644.	1.5	5
25	The Metabolic Syndrome and Biochemical Recurrence following Radical Prostatectomy. Prostate Cancer, 2011, 2011, 1-6.	0.6	33
26	Evidence Supports a Faster Growth Rate and/or Earlier Transformation to Clinically Significant Prostate Cancer in Black Than in White American Men, and Influences Racial Progression and Mortality Disparity. Journal of Urology, 2010, 183, 1792-1797.	0.4	246
27	Polymorphisms in glutathione S-transferase genes increase risk of prostate cancer biochemical recurrence differentially by ethnicity and disease severity. Cancer Causes and Control, 2009, 20, 1915-1926.	1.8	23
28	Racial Differences in Risk of Prostate Cancer Associated With Metabolic Syndrome. Urology, 2009, 74, 185-190.	1.0	70
29	CYP3A GENE CLUSTER, POPULATION STRATIFICATION, AND PROSTATE CANCER RISK. Journal of Urology, 2009, 181, 818-818.	0.4	1
30	EVIDENCE IN SUPPORT OF EARLIER PSA TESTING IN AFRICAN AMERICAN MEN AGE 35. Journal of Urology, 2009, 181, 642.	0.4	0
31	CLINICAL EVIDENCE SUPPORTS A FASTER GROWTH RATE FOR PROSTATE CANCER AMONG AFRICAN AMERICANS COMPARED TO EUROPEAN AMERICAN MEN. Journal of Urology, 2009, 181, 62-62.	0.4	2
32	RADICAL PROSTATECTOMY AS MONOTHERAPY OR AS PART OF MULTIMODAL MANAGEMENT OF HIGH GRADE PROSTATE CANCER WITH 10 YEAR MINIMUM FOLLOW UP. Journal of Urology, 2008, 179, 652-652.	0.4	1
33	Polycyclic Aromatic Hydrocarbon–DNA Adducts in Prostate and Biochemical Recurrence after Prostatectomy. Clinical Cancer Research, 2008, 14, 750-757.	7.0	24
34	Grilled Meat Consumption and PhIP-DNA Adducts in Prostate Carcinogenesis. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 803-808.	2.5	82
35	Associations between Smoking, Polymorphisms in Polycyclic Aromatic Hydrocarbon (PAH) Metabolism and Conjugation Genes and PAH-DNA Adducts in Prostate Tumors Differ by Race. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 1236-1245.	2.5	53
36	<i>SRD5A2</i> and <i>HSD3B2</i> polymorphisms are associated with prostate cancer risk and aggressiveness. Prostate, 2007, 67, 1654-1663.	2.3	32

CATHRYN H BOCK

#	Article	IF	CITATIONS
37	Racial differences in clinical and pathological associations with PhIP-DNA adducts in prostate. International Journal of Cancer, 2007, 121, 1319-1324.	5.1	16
38	Association between family history of prostate and breast cancer among African-American men with prostate cancer. Urology, 2006, 68, 1072-1076.	1.0	13
39	Prostate cancer risk from occupational exposure to polycyclic aromatic hydrocarbons interacting with the GSTP1 Ile105Val polymorphism. Cancer Detection and Prevention, 2006, 30, 412-422.	2.1	83
40	Sexually transmitted diseases and other urogenital conditions as risk factors for prostate cancer: a case–control study in Wayne County, Michigan. Cancer Causes and Control, 2005, 16, 263-273.	1.8	38
41	Decreasing age at prostate cancer diagnosis over successive generations in prostate cancer families. Prostate, 2005, 64, 60-66.	2.3	4
42	Association between Agent Orange and prostate cancer: a pilot case-control study. Urology, 2004, 63, 757-760.	1.0	35
43	Prostate cancer early detection practices among men with a family history of disease. Urology, 2003, 62, 470-475.	1.0	15
44	Analysis of the Prostate Cancer–Susceptibility Locus HPC20 in 172 Families Affected by Prostate Cancer. American Journal of Human Genetics, 2001, 68, 795-801.	6.2	51